Obesity exacerbates hypertension and stimulates the renin–angiotensin–aldosterone system (RAAS). Full-dose RAAS inhibition could be a therapeutic option in overweight or obese patients with hypertension. This study compared four RAAS inhibitors at full therapeutic doses to determine their effect on blood pressure (BP) and cardiovascular risk factors in these patients.

To demonstrate the benefits of perindopril 10 mg/indapamide 2,5 mg fixed combination in comparison with other variants of two-component antihypertensive therapy to achieve target blood pressure in association with metabolic neutrality. Design and methods. The study cohort included 60 patients (mean age 61,9 ± 11,7 years) with essential arterial hypertension, treated with two antihypertensive drugs and not achieved target blood pressure (